In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Sino Biopharmaceutical revealed it has entered into a strategic partnership with Boehringer Ingelheim to bring the German family-owned company’s innovative cancer therapies to the market in mainland China. 9 April 2024
Pharmaceutical
The US regulator has once more rebuffed efforts on the part of Supernus Pharmaceuticals to register its Parkinson’s disease candidate SPN-830. 9 April 2024
Pharmaceutical
UK health technology assessor the National Institute of Health and Care Excellence (NICE) has published final draft guidance recommending use of remdesivir for treating COVID-19 in eligible adults and children. 9 April 2024
Pharmaceutical
Of the 46 cancer drugs for which the US Food and Drug Administration (FDA) granted accelerated approval between 2013-2017, 63% were converted to regular approval even though only 43% demonstrated a clinical benefit in confirmatory trials after more than five years of follow-up, according to a study presented at the American Association for Cancer Research (AACR) 2024 annual meeting. 9 April 2024
Biosimilars
The USA-based Biosimilars Council, the leading trade association representing manufacturers of biosimilar medicines, has released a new analysis of IQVIA data revealing health plans and patients missed out on savings up to $6 billion as a result of rebate schemes by pharmacy benefit managers. 9 April 2024
Pharmaceutical
An FXR agonist developed by Ascletis Pharma has not performed well in mid-stage trials, leading the Hangzhou, China-based firm to dial down its investment in the drug. 8 April 2024
Biotechnology
Increasing interest in targeted therapies is driving demand in the antibody discovery market, finds industry analyst Future Market Insights. 8 April 2024
Pharmaceutical
Family-controlled Spanish pharma company Esteve today announced the appointment of Jacob Tolstrup as chief business development officer, part of the executive management and reporting to Staffan Schüberg, chief executive of the company. 8 April 2024
Biotechnology
Two frequent words that people often hear in recent China’s pharma industry comments are “Chu Hai” and “Nei Juan”. The former means “selling overseas,” while the latter means “cut throat competition.” 8 April 2024
Generics
Generic drugs are known to be an effective cost-containment measure for healthcare systems. 8 April 2024
Pharmaceutical
Providing continuing competition to market leader Gilead Sciences, ViiV Healthcare has achieved a new milestone in the HIV space. 8 April 2024
Biosimilars
South Korean drugmaker Samsung Bioepis today released its Second Quarter 2024 Biosimilars Market report, which includes the latest average sales price (ASP) information of all biosimilars and reference products available in the US market. 8 April 2024
Biotechnology
US pharma giant Merck & Co is making another foray into the antibody-drug conjugates (ADCs) space, with the acquisition of Abceutics. 8 April 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved Johnson & Johnson and Legend Biotech’s Carvykti (ciltacabtagene autoleucel) in a new indication. 8 April 2024
Biotechnology
Swiss ophthalmology specialist Oculis Holding has announced that Dr Eric Donnenfeld, presented the positive results from the Phase III OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 American Society of Cataract and Refractive Surgery (ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA. 8 April 2024
Pharmaceutical
British life sciences investor Medicxi is betting $40 million on a Shanghai-based company, D3 Bio, working in the areas of oncology and immunology. 8 April 2024
Biotechnology
After a previous delay last November, and a positive AdCom recommendation last month, the US Food and Drug Administration (FDA) has now approved an additional indication for Abecma (idecabtagene vicleucel; ide-cel). 8 April 2024
Pharmaceutical
The New England Journal of Medicine has published new data on Jardiance (empagliflozin) from a Phase III trial. 8 April 2024
Pharmaceutical
New interim results from the Phase III EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia were presented on Saturday at the Annual Congress of the Schizophrenia International Research Society (SIRS). 8 April 2024
Biotechnology
Swiss pharma giant Novartis on Saturday presented new real-world data on its Leqvio (inclisiran) at the 2024 American College of Cardiology's Annual Scientific Session & Expo. 8 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze